JP2001501801A - モノクローナル抗体br110およびその使用 - Google Patents
モノクローナル抗体br110およびその使用Info
- Publication number
- JP2001501801A JP2001501801A JP09515854A JP51585497A JP2001501801A JP 2001501801 A JP2001501801 A JP 2001501801A JP 09515854 A JP09515854 A JP 09515854A JP 51585497 A JP51585497 A JP 51585497A JP 2001501801 A JP2001501801 A JP 2001501801A
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- tissue
- antibody
- monoclonal antibody
- ligand
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.GA733−1抗原を特異的に認識し結合するがGA733−2抗原は認識 せず結合もしないリガンド。 2.リガンドが腫瘍原性組織を特異的に認識し結合するが、正常組織は認識せず 結合もしない請求項1記載のリガンド。 3.ATCC番号HB11698と命名されたハイブリドーマによって産生され るモノクローナル抗体BR110。 4.リガンドがGA733−1抗原とコンプレックスを形成し、GA733−1 抗原が細胞表面にある場合、前記リガンドが細胞内にインターナライズされる請 求項1記載のリガンド。 5.BR110と命名されたモノクローナル抗体である請求項1記載のリガンド 。 6.BR110モノクローナル抗体を産生するハイブリドーマ。 7.少なくとも1つの機能的活性セグメントを含む部分である、細胞傷害剤の少 なくとも1部分に結合された請求項1のリガンドを含んでなる結合体。 8.細胞傷害剤が酵素、リンフォカイン、オンコスタチンまたは毒素である請求 項7記載の結合体。 9.検出可能なマーカーで標識された請求項2記載のモノクローナル抗体。 10.検出可能なマーカーが酵素、常磁性同位元素、ビオチン、フルオロフォア 、クロモフォア、重金属または放射性同位元素である請求項9記載のモノクロー ナル抗体。 11.請求項2のモノクローナル抗体の抗原結合部位を有するFv 分子。 12.sFv分子である請求項11のFv分子。 13.請求項2のモノクローナル抗体の抗原結合部位を有するFab分子。 14.請求項2のモノクローナル抗体の抗原結合部位を有するFab’分子。 15.請求項2のモノクローナル抗体の抗原結合部位を有するF(ab’)2分 子。 16.2種類の異なる抗原に結合特異性を有する二重特異性抗体であって、抗原 の1つは請求項2のモノクローナル抗体が結合する抗原である二重特異性抗体。 17.抗原結合領域が、ハイブリドーマHB11698によって産生されるモノ クローナル抗体BR110の、その標的抗原への免疫特異的結合を競合的に阻止 するヒト/ネズミ組み換え抗体。 18.対象からの組織切片中のBR110抗原を検出する方法であって、組織切 片と請求項2のモノクローナル抗体とを、前記抗体が前記組織切片に結合する条 件下で接触させ、前記組織切片に結合した抗体を検出し、それによって組織切片 中のBR110を検出する各段階を含む方法。 19.組織切片が、正常組織の特徴がBR110抗原が存在しないことであり、 悪性腫瘍組織の特徴がBR110抗原が存在することであるような組織の切片で ある請求項18記載の方法。 20.悪性腫瘍組織が腺癌である請求項19記載の方法。 21.組織切片が胃腸組織である請求項19記載の方法。 22.組織切片が胸部組織である請求項19記載の方法。 23.組織切片が結腸組織である請求項19記載の方法。 24.組織切片が肺組織である請求項19記載の方法。 25.組織切片に結合したモノクローナル抗体と、検出可能なマーカーで標識し た第2の抗体とを、第2の抗体がモノクローナル抗体と結合する条件下で接触さ せ、このように結合した第2の抗体を検出することによって、組織切片に結合し たモノクローナル抗体を検出する請求項19記載の方法。 26.試験すべき悪性腫瘍からの組織切片のBR110抗原の分布量の差を、正 常組織からの組織切片のBR110抗原の量および分布に対して測定する方法で あって、試験すべき組織と正常組織の両方を請求項2のモノクローナル抗体と接 触させ、それによってBR110抗原の量および分布の差を検出する各段階を含 む方法。 27.対象から組織サンプルを採取し、このような組織切片中のBR110抗原 を請求項26の方法を用いて検出し、それによってそのような悪性腫瘍疾患を診 断する各段階を含む対象の悪性腫瘍疾患診断法。 28.検出可能な試剤が付着結合している請求項2のモノクローナル抗体を含む 組成物。 29.検出可能な試剤がリシン、ジフテリア毒素、ブリオジン、シュードモナス 、エキソトキシン−A、アブリン、サポリン、およびゲロニンからなる群から選 択される毒素を含んでなる請求項28記載の組成物。 30.検出可能な試剤が酵素、薬剤、またはDNA断片を含む請求項28記載の 組成物。 31.請求項1のリガンドをコード化する核酸分子。 32.請求項31の核酸分子を含むプラスミド。 33.適切なホスト細胞中の請求項32のプラスミドを含んでなるホストベクタ ー系。 34.請求項33のホストベクター系を増殖させてホストに蛋白質を産生させ、 このようにして産生した蛋白質を回収する各段階を含む蛋白質の製造方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US564195P | 1995-10-19 | 1995-10-19 | |
US60/005,641 | 1995-10-19 | ||
PCT/US1996/016070 WO1997014796A1 (en) | 1995-10-19 | 1996-10-07 | Monoclonal antibody br110 and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2001501801A true JP2001501801A (ja) | 2001-02-13 |
Family
ID=21716930
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP09515854A Ceased JP2001501801A (ja) | 1995-10-19 | 1996-10-07 | モノクローナル抗体br110およびその使用 |
Country Status (11)
Country | Link |
---|---|
US (1) | US5840854A (ja) |
EP (1) | EP0856054B1 (ja) |
JP (1) | JP2001501801A (ja) |
AT (1) | ATE265532T1 (ja) |
AU (1) | AU7394296A (ja) |
CA (1) | CA2235269C (ja) |
DE (1) | DE69632333T2 (ja) |
ES (1) | ES2219699T3 (ja) |
IL (1) | IL123294A0 (ja) |
NO (1) | NO321548B1 (ja) |
WO (1) | WO1997014796A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007277184A (ja) * | 2006-04-07 | 2007-10-25 | Central Res Inst Of Electric Power Ind | 抗鉛モノクローナル抗体 |
WO2011145744A1 (ja) * | 2010-05-17 | 2011-11-24 | 株式会社リブテック | in vivoで抗腫瘍活性を有する抗ヒトTROP-2抗体 |
US9427464B2 (en) | 2011-11-22 | 2016-08-30 | Chiome Bioscience Inc. | Anti-human TROP-2 antibody having an antitumor activity in vivo |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7354587B1 (en) * | 1994-07-06 | 2008-04-08 | Immunomedics, Inc. | Use of immunoconjugates to enhance the efficacy of multi-stage cascade boosting vaccines |
US6136311A (en) | 1996-05-06 | 2000-10-24 | Cornell Research Foundation, Inc. | Treatment and diagnosis of cancer |
US6366762B1 (en) * | 1999-03-31 | 2002-04-02 | Qualcomm, Inc. | System and method for measuring round trip delay on the paging and access channels |
US6617432B1 (en) * | 1999-10-15 | 2003-09-09 | University Of Pittsburgh | Nuclear matrix proteins polynucleotide sequences encoding them and their use |
US20030009781A1 (en) * | 2001-03-29 | 2003-01-09 | Allen Keith D. | Transgenic mice containing Kir3.3 potassium channel gene disruptions |
US20020155109A1 (en) * | 2001-04-20 | 2002-10-24 | Lynch David H. | Bispecific antibodies that bind TRAIL-R1 and TRAIL-R2 |
US8435529B2 (en) | 2002-06-14 | 2013-05-07 | Immunomedics, Inc. | Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy |
US9745380B2 (en) | 2002-03-01 | 2017-08-29 | Immunomedics, Inc. | RS7 antibodies |
EP1483295B1 (en) | 2002-03-01 | 2008-12-10 | Immunomedics, Inc. | Rs7 antibodies |
US9770517B2 (en) * | 2002-03-01 | 2017-09-26 | Immunomedics, Inc. | Anti-Trop-2 antibody-drug conjugates and uses thereof |
US9701754B1 (en) | 2002-10-23 | 2017-07-11 | City Of Hope | Covalent disulfide-linked diabodies and uses thereof |
US20080213267A1 (en) * | 2006-02-24 | 2008-09-04 | Arius Research, Inc. | Cytotoxicity mediation of cells evidencing surface expression of TROP-2 |
US20080131428A1 (en) * | 2006-02-24 | 2008-06-05 | Arius Research, Inc. | Cytotoxicity mediation of cells evidencing surface expression of TROP-2 |
US7420040B2 (en) * | 2006-02-24 | 2008-09-02 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of TROP-2 |
US20080305104A1 (en) * | 2006-02-24 | 2008-12-11 | Young David S F | Cytotoxicity mediation of cells evidencing surface expression of TROP-2 |
ATE509033T1 (de) | 2006-03-20 | 2011-05-15 | Univ California | Manipulierte anti-prostatastammzellenantigen (psca)-antikörper für krebs-targeting |
US8940298B2 (en) | 2007-09-04 | 2015-01-27 | The Regents Of The University Of California | High affinity anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting and detection |
EP3495000A1 (en) | 2009-02-17 | 2019-06-12 | Cornell Research Foundation, Inc. | Methods and kits for diagnosis of cancer and prediction of therapeutic value |
MX354143B (es) | 2009-12-02 | 2018-02-14 | Imaginab Inc | Minicuerpos j591 y diacuerpos-cys para apuntar con especificidad de objetivo a un antígeno de membrana específico para próstata de humano (psma) y métodos para su uso. |
JPWO2011155579A1 (ja) * | 2010-06-10 | 2013-08-15 | 北海道公立大学法人 札幌医科大学 | 抗Trop−2抗体 |
EP2776470A2 (en) | 2011-11-11 | 2014-09-17 | Rinat Neuroscience Corporation | Antibodies specific for trop-2 and their uses |
AU2015219495B2 (en) | 2014-02-21 | 2019-11-21 | Ibc Pharmaceuticals, Inc. | Disease therapy by inducing immune response to Trop-2 expressing cells |
CA2981543A1 (en) | 2015-04-22 | 2016-10-27 | Immunomedics, Inc. | Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells |
KR20180050321A (ko) | 2015-08-07 | 2018-05-14 | 이미지냅 인코포레이티드 | 분자를 표적화하기 위한 항원 결합 구조체 |
WO2018147960A1 (en) | 2017-02-08 | 2018-08-16 | Imaginab, Inc. | Extension sequences for diabodies |
EP3876998A1 (en) | 2018-11-05 | 2021-09-15 | Synaffix B.V. | Antibody-conjugates for targeting of tumours expressing trop-2 |
US20210316003A1 (en) | 2020-03-20 | 2021-10-14 | Immunomedics, Inc. | Biomarkers for sacituzumab govitecan therapy |
KR20230086712A (ko) | 2020-10-14 | 2023-06-15 | 상하이 한서 바이오메디컬 컴퍼니 리미티드 | 항-trop-2 항체, 이의 항원-결합 단편 또는 이의 돌연변이체, 및 이의 의학적 용도 |
CN115429893A (zh) | 2021-06-02 | 2022-12-06 | 百奥泰生物制药股份有限公司 | 药物偶联物及其用途 |
KR20240058146A (ko) | 2021-09-23 | 2024-05-03 | 상하이 한서 바이오메디컬 컴퍼니 리미티드 | 항체-약물 접합체, 이의 제조 방법 및 의약적 용도 |
WO2023180485A1 (en) | 2022-03-23 | 2023-09-28 | Synaffix B.V. | Antibody-conjugates for targeting of tumours expressing trop-2 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5185254A (en) * | 1988-12-29 | 1993-02-09 | The Wistar Institute | Gene family of tumor-associated antigens |
JPH0829101B2 (ja) * | 1989-04-21 | 1996-03-27 | アメリカ合衆国 | 組換え抗体―毒素融合タンパク質 |
EP0609292A4 (en) * | 1991-10-18 | 1995-10-25 | Wistar Inst | Soluble variants of type i membrane proteins, and methods of using them. |
-
1996
- 1996-10-07 DE DE69632333T patent/DE69632333T2/de not_active Expired - Fee Related
- 1996-10-07 AT AT96936244T patent/ATE265532T1/de not_active IP Right Cessation
- 1996-10-07 IL IL12329496A patent/IL123294A0/xx unknown
- 1996-10-07 EP EP96936244A patent/EP0856054B1/en not_active Expired - Lifetime
- 1996-10-07 CA CA002235269A patent/CA2235269C/en not_active Expired - Fee Related
- 1996-10-07 WO PCT/US1996/016070 patent/WO1997014796A1/en active IP Right Grant
- 1996-10-07 US US08/726,528 patent/US5840854A/en not_active Expired - Fee Related
- 1996-10-07 AU AU73942/96A patent/AU7394296A/en not_active Abandoned
- 1996-10-07 ES ES96936244T patent/ES2219699T3/es not_active Expired - Lifetime
- 1996-10-07 JP JP09515854A patent/JP2001501801A/ja not_active Ceased
-
1998
- 1998-04-17 NO NO19981745A patent/NO321548B1/no unknown
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007277184A (ja) * | 2006-04-07 | 2007-10-25 | Central Res Inst Of Electric Power Ind | 抗鉛モノクローナル抗体 |
JP4689521B2 (ja) * | 2006-04-07 | 2011-05-25 | 財団法人電力中央研究所 | 抗鉛モノクローナル抗体 |
WO2011145744A1 (ja) * | 2010-05-17 | 2011-11-24 | 株式会社リブテック | in vivoで抗腫瘍活性を有する抗ヒトTROP-2抗体 |
JPWO2011145744A1 (ja) * | 2010-05-17 | 2013-07-22 | 株式会社リブテック | invivoで抗腫瘍活性を有する抗ヒトTROP−2抗体 |
US9062100B2 (en) | 2010-05-17 | 2015-06-23 | Livtech, Inc. | Anti-human TROP-2 antibody having anti-tumor activity in vivo |
JP2015221793A (ja) * | 2010-05-17 | 2015-12-10 | 株式会社カイオム・バイオサイエンス | invivoで抗腫瘍活性を有する抗ヒトTROP−2抗体 |
JP5859434B2 (ja) * | 2010-05-17 | 2016-02-10 | 株式会社カイオム・バイオサイエンス | invivoで抗腫瘍活性を有する抗ヒトTROP−2抗体 |
KR101624381B1 (ko) * | 2010-05-17 | 2016-05-25 | 가부시키가이샤 리부텍쿠 | in vivo 에서 항종양 활성을 갖는 항인간 TROP-2 항체 |
US9670287B2 (en) | 2010-05-17 | 2017-06-06 | Chiome Bioscience Inc. | Anti-human TROP-2 antibody having anti-tumor activity in vivo |
EA031043B1 (ru) * | 2010-05-17 | 2018-11-30 | Ливтех, Инк. | Антитело против trop-2 человека, обладающее противоопухолевой активностью in vivo |
US9427464B2 (en) | 2011-11-22 | 2016-08-30 | Chiome Bioscience Inc. | Anti-human TROP-2 antibody having an antitumor activity in vivo |
US10202461B2 (en) | 2011-11-22 | 2019-02-12 | Chiome Bioscience Inc. | Anti-human TROP-2 antibody having an antitumor activity in vivo |
Also Published As
Publication number | Publication date |
---|---|
NO321548B1 (no) | 2006-05-29 |
WO1997014796A1 (en) | 1997-04-24 |
NO981745D0 (no) | 1998-04-17 |
NO981745L (no) | 1998-04-17 |
EP0856054A1 (en) | 1998-08-05 |
CA2235269A1 (en) | 1997-04-24 |
CA2235269C (en) | 2006-09-19 |
AU7394296A (en) | 1997-05-07 |
US5840854A (en) | 1998-11-24 |
EP0856054B1 (en) | 2004-04-28 |
DE69632333T2 (de) | 2004-12-30 |
DE69632333D1 (de) | 2004-06-03 |
IL123294A0 (en) | 1998-09-24 |
ATE265532T1 (de) | 2004-05-15 |
ES2219699T3 (es) | 2004-12-01 |
MX9802129A (es) | 1998-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0856054B1 (en) | Monoclonal antibody br110 and uses thereof | |
JP2761012B2 (ja) | 組換dna産物及び方法 | |
Wels et al. | Construction, bacterial expression and characterization of a bifunctional single–chain antibody–phosphatase fusion protein targeted to the human ERBB–2 receptor | |
EP2817339B1 (en) | Anti sez6 antibodies and methods of use | |
JP3492373B2 (ja) | モノクローナル抗体 | |
CN111670045A (zh) | Ror1特异性抗原结合分子 | |
EP0699756B1 (en) | Mutant BR96 antibodies reactive with human carcinomas | |
JP6326137B2 (ja) | 抗her2抗体及びその結合体 | |
EP0521842B1 (en) | Tumor antigen specific antibody | |
CN111777681A (zh) | 一种结合紧密连接蛋白-18.2的抗体及其用途 | |
US11390686B2 (en) | HER3 binding agents and uses thereof | |
WO2019062877A1 (zh) | 结合至纤维连接蛋白b结构域的蛋白 | |
CA2557482C (en) | Target for b-cell disorders | |
US6787638B1 (en) | Tumor specific human monoclonal antibodies and methods of use | |
KR20230124037A (ko) | 종양 특이적 claudin 18.2 항체-약물 접합체 | |
KR20050007376A (ko) | 인간 암배항원에 특이적인 항체 단편 | |
US5728821A (en) | Mutant BR96 antibodies reactive with human carcinomas | |
US20230002503A1 (en) | Nano-antibody targeting caix antigen and application thereof | |
KR20220160670A (ko) | 항 pd-l1 및 pd-l2 항체 및 이의 유도체 및 용도 | |
CN115505043A (zh) | 特异性结合糖基化ceacam5的抗体 | |
KR102090444B1 (ko) | 항-icam4 항체 및 icam4 발현 세포와 관련된 질병의 진단 및 치료용 조성물 | |
WO2023222068A1 (en) | Anti-cd200r1 antibodies | |
WO2024012434A1 (en) | Antibody, antigen-binding fragment thereof, and pharmaceutical use thereof | |
WO2024008112A1 (en) | Anti-ror1 antibodies | |
WO2017147247A1 (en) | Anti-sas1b antibodies and methods of use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070130 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070501 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070618 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070629 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070720 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070813 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080115 |
|
RD13 | Notification of appointment of power of sub attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7433 Effective date: 20080201 |
|
A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20080617 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20080812 |